{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:24:24Z","timestamp":1784715864426,"version":"3.55.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG057709"],"award-info":[{"award-number":["R01AG057709"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00210-021-02188-x","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T07:00:52Z","timestamp":1638342052000},"page":"27-38","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Metalloproteinases and their inhibitors in neurological disease"],"prefix":"10.1007","volume":"395","author":[{"given":"Edgar R.","family":"Lopez-Navarro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"key":"2188_CR1","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1161\/01.STR.0000127420.10990.76","volume":"35","author":"JC Adair","year":"2004","unstructured":"Adair JC, Charlie J, Dencoff JE, Kaye JA, Quinn JF, Camicioli RM, Stetler-Stevenson WG, Rosenberg GA (2004) Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke 35:e159\u2013e162","journal-title":"Stroke"},{"key":"2188_CR2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejmech.2017.02.014","volume":"129","author":"N Adhikari","year":"2017","unstructured":"Adhikari N, Mukherjee A, Saha A, Jha T (2017) Arylsulfonamides and selectivity of matrix metalloproteinase-2: an overview. Eur J Med Chem 129:72\u2013109","journal-title":"Eur J Med Chem"},{"issue":"Pt 1","key":"2188_CR3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1042\/bj3090299","volume":"309","author":"JA Allan","year":"1995","unstructured":"Allan JA, Docherty AJ, Barker PJ, Huskisson NS, Reynolds JJ, Murphy G (1995) Binding of gelatinases A and B to type-I collagen and other matrix components. Biochemical Journal 309(Pt 1):299\u2013306","journal-title":"Biochemical Journal"},{"key":"2188_CR4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/ane.12296","volume":"131","author":"MR Amiri-Nikpour","year":"2015","unstructured":"Amiri-Nikpour MR, Nazarbaghi S, Hamdi-Holasou M, Rezaei Y (2015) An open-label evaluator-blinded clinical study of minocycline neuroprotection in ischemic stroke: gender-dependent effect. Acta Neurol Scand 131:45\u201350","journal-title":"Acta Neurol Scand"},{"key":"2188_CR5","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.05.028","volume":"25","author":"Y Arslan","year":"2016","unstructured":"Arslan Y, Arslan \u0130B, Pek\u00e7evik Y, \u015eener U, K\u00f6se \u015e, Zorlu Y (2016) Matrix metalloproteinase levels in cervical and intracranial carotid dolichoarteriopathies. J Stroke Cerebrovas Dis 25:2153\u20138","journal-title":"J Stroke Cerebrovas Dis"},{"key":"2188_CR6","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1001\/jama.2020.5230","volume":"323","author":"BT Baxter","year":"2020","unstructured":"Baxter BT, Matsumura J, Curci JA, McBride R, Larson L, Blackwelder W, Lam D, Wijesinha M, Terrin M, N-TA3CT Investigators (2020) Effect of doxycycline on aneurysm growth among patients with small infrarenal abdominal aortic aneurysms: a randomized clinical trial. JAMA 323:2029\u20132038. https:\/\/doi.org\/10.1001\/jama.2020.5230","journal-title":"JAMA"},{"key":"2188_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mva.2002.125018","volume":"36","author":"BT Baxter","year":"2002","unstructured":"Baxter BT, Pearce WH, Waltke EA, Littooy FN, Hallett JW Jr, Kent KC, Upchurch GR Jr, Chaikof EL, Mills JL, Fleckten B, Longo GM, Lee JK, Thompson RW (2002) Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (phase II) multicenter study. J Vasc Surg 36:1\u201312","journal-title":"J Vasc Surg"},{"key":"2188_CR8","doi-asserted-by":"crossref","unstructured":"Behl T, Kaur G, Sehgal A, Bhardwaj S, Singh S, Buhas C, Judea-Pusta C, Uivarosan D, Munteanu MA, Bungau S (2021) \u2018Multifaceted role of matrix metalloproteinases in neurodegenerative diseases: pathophysiological and therapeutic perspectives\u2019. Int J Mol Sci, 22","DOI":"10.3390\/ijms22031413"},{"key":"2188_CR9","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3233\/JAD-2011-110566","volume":"27","author":"M Bjerke","year":"2011","unstructured":"Bjerke M, Zetterberg H, Edman \u00c5, Blennow K, Wallin A, Andreasson U (2011) Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer\u2019s disease. J Alzheimers Dis 27:665\u2013676","journal-title":"J Alzheimers Dis"},{"key":"2188_CR10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00004850-200411000-00004","volume":"19","author":"RM Bonelli","year":"2004","unstructured":"Bonelli RM, H\u00f6dl AK, Hofmann P, Kapfhammer HP (2004) Neuroprotection in Huntington\u2019s disease: a 2-year study on minocycline. Int Clin Psychopharmacol 19:337\u2013342","journal-title":"Int Clin Psychopharmacol"},{"key":"2188_CR11","doi-asserted-by":"crossref","first-page":"212553","DOI":"10.7573\/dic.212553","volume":"8","author":"S Cankaya","year":"2019","unstructured":"Cankaya S, Cankaya B, Kilic U, Kilic E, Yulug B (2019) The therapeutic role of minocycline in Parkinson\u2019s disease. Drugs Context 8:212553","journal-title":"Drugs Context"},{"key":"2188_CR12","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.phrs.2011.05.005","volume":"64","author":"MM Castro","year":"2011","unstructured":"Castro MM, Kandasamy AD, Youssef N, Schulz R (2011) Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases. Pharmacol Res 64:551\u2013560","journal-title":"Pharmacol Res"},{"key":"2188_CR13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10072-017-3166-4","volume":"39","author":"J Cheng","year":"2018","unstructured":"Cheng J, Liu HP, Lee CC, Chen MY, Lin WY, Tsai FJ (2018) Matrix metalloproteinase 14 modulates diabetes and Alzheimer\u2019s disease cross-talk: a meta-analysis. Neurol Sci 39:267\u2013274","journal-title":"Neurol Sci"},{"key":"2188_CR14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1471-4159.2008.05399.x","volume":"106","author":"DH Choi","year":"2008","unstructured":"Choi DH, Kim EM, Son HJ, Joh TH, Kim YS, Kim D, Flint Beal M, Hwang O (2008) A novel intracellular role of matrix metalloproteinase-3 during apoptosis of dopaminergic cells. J Neurochem 106:405\u2013415","journal-title":"J Neurochem"},{"key":"2188_CR15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbamcr.2009.07.004","volume":"1803","author":"M Fanjul-Fern\u00e1ndez","year":"2010","unstructured":"Fanjul-Fern\u00e1ndez M, Folgueras AR, Cabrera S, L\u00f3pez-Ot\u00edn C (2010) Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochem Biophys Acta 1803:3\u201319","journal-title":"Biochem Biophys Acta"},{"key":"2188_CR16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0014-5793(00)02380-2","volume":"487","author":"G Forloni","year":"2001","unstructured":"Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M (2001) Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett 487:404\u2013407","journal-title":"FEBS Lett"},{"key":"2188_CR17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000113733","volume":"25","author":"T Frenzel","year":"2008","unstructured":"Frenzel T, Lee CZ, Kim H, Quinnine NJ, Hashimoto T, Lawton MT, Guglielmo BJ, McCulloch CE, Young WL (2008) Feasibility of minocycline and doxycycline use as potential vasculostatic therapy for brain vascular malformations: pilot study of adverse events and tolerance. Cerebrovasc Dis 25:157\u2013163","journal-title":"Cerebrovasc Dis"},{"key":"2188_CR18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0165-5728(92)90192-N","volume":"41","author":"K Gijbels","year":"1992","unstructured":"Gijbels K, Masure S, Carton H, Opdenakker G (1992) Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 41:29\u201334","journal-title":"J Neuroimmunol"},{"key":"2188_CR19","doi-asserted-by":"crossref","first-page":"C539","DOI":"10.1152\/ajpcell.00047.2010","volume":"299","author":"MO Griffin","year":"2010","unstructured":"Griffin MO, Fricovsky E, Ceballos G, Villarreal F (2010) \u2018Tetracyclines: a pleitropic family of compounds with promising therapeutic properties Review of the Literature.\u2019 Am J Physiol Cell Physiol 299:C539\u2013C548","journal-title":"Am J Physiol Cell Physiol"},{"key":"2188_CR20","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/infdis\/jiw385","volume":"214","author":"J Gutierrez","year":"2016","unstructured":"Gutierrez J, Menshawy K, Goldman J, Dwork AJ, Elkind MS, Marshall RS, Morgello S (2016) Metalloproteinases and brain arterial remodeling among individuals with and those without HIV infection. J Infect Dis 214:1329\u20131335","journal-title":"J Infect Dis"},{"key":"2188_CR21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrneurol.2010.181","volume":"7","author":"J Gutierrez","year":"2011","unstructured":"Gutierrez J, Sacco RL, Wright CB (2011) Dolichoectasia-an evolving arterial disease. Nat Rev Neurol 7:41\u201350","journal-title":"Nat Rev Neurol"},{"key":"2188_CR22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jvs.2008.03.064","volume":"48","author":"AE Hackmann","year":"2008","unstructured":"Hackmann AE, Rubin BG, Sanchez LA, Geraghty PA, Thompson RW, Curci JA (2008) A randomized, placebo-controlled trial of doxycycline after endoluminal aneurysm repair. J Vasc Surg 48:519\u201326 (discussion 26)","journal-title":"J Vasc Surg"},{"key":"2188_CR23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1474-4422(13)70307-7","volume":"13","author":"S Ha\u00efk","year":"2014","unstructured":"Ha\u00efk S, Marcon G, Mallet A, Tettamanti M, Welaratne A, Giaccone G, Azimi S, Pietrini V, Fabreguettes JR, Imperiale D, Cesaro P, Buffa C, Aucan C, Lucca U, Peckeu L, Suardi S, Tranchant C, Zerr I, Houillier C, Redaelli V, Vespignani H, Campanella A, Sellal F, Krasnianski A, Seilhean D, Heinemann U, Sedel F, Canovi M, Gobbi M, Di Fede G, Laplanche JL, Pocchiari M, Salmona M, Forloni G, Brandel JP, Tagliavini F (2014) Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 13:150\u2013158","journal-title":"Lancet Neurol"},{"key":"2188_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2377-5-1","volume":"5","author":"T Hashimoto","year":"2005","unstructured":"Hashimoto T, Matsumoto MM, Li JF, Lawton MT, Young WL (2005) Suppression of MMP-9 by doxycycline in brain arteriovenous malformations. BMC Neurol 5:1","journal-title":"BMC Neurol"},{"key":"2188_CR25","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.12.036","volume":"26","author":"T He","year":"2017","unstructured":"He T, Wang J, Wang XL, Deng WS, Sun P (2017) Association between the matrix metalloproteinase-9 rs3918242 polymorphism and ischemic stroke susceptibility: a meta-analysis. J Stroke Cerebrovasc Dis 26:1136\u20131143","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2188_CR26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaneurol.2019.3762","volume":"77","author":"R Howard","year":"2020","unstructured":"Howard R, Zubko O, Bradley R, Harper E, Pank L, O\u2019Brien J, Fox C, Tabet N, Livingston G, Bentham P, McShane R, Burns A, Ritchie C, Reeves S, Lovestone S, Ballard C, Noble W, Nilforooshan R, Wilcock G, Gray R (2020) Minocycline at 2 different dosages vs placebo for patients with mild alzheimer disease: a randomized clinical trial. JAMA Neurol 77:164\u2013174","journal-title":"JAMA Neurol"},{"key":"2188_CR27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.brainres.2017.08.009","volume":"1674","author":"X Huang","year":"2017","unstructured":"Huang X, Ye Q, Zhang Z, Huang X, Zhu Z, Chen Y, Li J, Chen S, Xia N, Mao X, Han L, Ye Z (2017) Association of matrix metalloproteinase-3 gene 5A\/6A polymorphism with the recurrence of ischemic stroke: a prospective observational study. Brain Res 1674:55\u201361","journal-title":"Brain Res"},{"key":"2188_CR28","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1097\/QAD.0000000000001943","volume":"32","author":"MD Hunter","year":"2018","unstructured":"Hunter MD, Shenoy A, Dwork A, Elkind MSV, Marshall R, Mohr JP, Morgello S, Gutierrez J (2018) Brain vascular intima vulnerability among HIV-positive and negative individuals. AIDS 32:2209\u20132216","journal-title":"AIDS"},{"key":"2188_CR29","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/mds.23236","volume":"25","author":"Investigators, The Huntington Study Group DOMINO","year":"2010","unstructured":"Investigators, The Huntington Study Group DOMINO (2010) A futility study of minocycline in Huntington\u2019s disease. Mov Disord 25:2219\u20132224","journal-title":"Mov Disord"},{"key":"2188_CR30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/14756366.2016.1161620","volume":"31","author":"A Jab\u0142o\u0144ska-Trypu\u0107","year":"2016","unstructured":"Jab\u0142o\u0144ska-Trypu\u0107 A, Matejczyk M, Rosochacki S (2016) Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem 31:177\u2013183","journal-title":"J Enzyme Inhib Med Chem"},{"key":"2188_CR31","first-page":"300060520926427","volume":"48","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Liu H, Wang Y, Shi X, Shao Y, Xu Z (2020) Meta-analysis of matrix metalloproteinase (MMP)-9 C1562T polymorphism and susceptibility to ischemic stroke in the Chinese population. J Int Med Res 48:300060520926427","journal-title":"J Int Med Res"},{"key":"2188_CR32","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1161\/STROKEAHA.113.000780","volume":"44","author":"E Kohler","year":"2013","unstructured":"Kohler E, Prentice DA, Bates TR, Hankey GJ, Claxton A, van Heerden J, Blacker D (2013) Intravenous minocycline in acute stroke. Stroke 44:2493\u20132499","journal-title":"Stroke"},{"key":"2188_CR33","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1212\/01.wnl.0000277487.04281.db","volume":"69","author":"Y Lampl","year":"2007","unstructured":"Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, Anca-Hershkowitz M, Sadeh M (2007) Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 69:1404\u20131410","journal-title":"Neurology"},{"key":"2188_CR34","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nrn3550","volume":"14","author":"LW Lau","year":"2013","unstructured":"Lau LW, Cua R, Keough MB, Haylock-Jacobs S, Yong VW (2013) Pathophysiology of the brain extracellular matrix: a new target for remyelination. Nat Rev Neurosci 14:722\u2013729","journal-title":"Nat Rev Neurosci"},{"key":"2188_CR35","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.17219\/acem\/110319","volume":"28","author":"AM Lech","year":"2019","unstructured":"Lech AM, Wiera G, Mozrzymas JW (2019) Matrix metalloproteinase-3 in brain physiology and neurodegeneration. Adv Clin Exp Med 28:1717\u20131722","journal-title":"Adv Clin Exp Med"},{"key":"2188_CR36","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1161\/CIRCULATIONAHA.108.806505","volume":"119","author":"JH Lindeman","year":"2009","unstructured":"Lindeman JH, Abdul-Hussien H, van Bockel JH, Wolterbeek R, Kleemann R (2009) Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation 119:2209\u20132216","journal-title":"Circulation"},{"key":"2188_CR37","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1532-5415.2004.52109.x","volume":"52","author":"MB Loeb","year":"2004","unstructured":"Loeb MB, Molloy DW, Smieja M, Standish T, Goldsmith CH, Mahony J, Smith S, Borrie M, Decoteau E, Davidson W, McDougall A, Gnarpe J, O\u2019DONNell M, Chernesky M (2004) A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer\u2019s disease. J Am Geriatr Soc 52:381\u20137","journal-title":"J Am Geriatr Soc"},{"key":"2188_CR38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1017\/S1041610207005790","volume":"20","author":"S Lorenzl","year":"2008","unstructured":"Lorenzl S, Buerger K, Hampel H, Beal MF (2008) Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. Int Psychogeriatr 20:67\u201376","journal-title":"Int Psychogeriatr"},{"key":"2188_CR39","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/cpt1973145852","volume":"14","author":"H Macdonald","year":"1973","unstructured":"Macdonald H, Kelly RG, Allen ES, Noble JF, Kanegis LA (1973) Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther 14:852\u2013861","journal-title":"Clin Pharmacol Ther"},{"key":"2188_CR40","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1161\/STROKEAHA.109.556852","volume":"40","author":"LS Machado","year":"2009","unstructured":"Machado LS, Sazonova IY, Kozak A, Wiley DC, El-Remessy AB, Ergul A, Hess DC, Waller JL, Fagan SC (2009) Minocycline and tissue-type plasminogen activator for stroke. Stroke 40:3028\u20133033","journal-title":"Stroke"},{"key":"2188_CR41","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00415-018-8935-3","volume":"265","author":"K Malhotra","year":"2018","unstructured":"Malhotra K, Chang JJ, Khunger A, Blacker D, Switzer JA, Goyal N, Hernandez AV, Pasupuleti V, Alexandrov AV, Tsivgoulis G (2018) Minocycline for acute stroke treatment: a systematic review and meta-analysis of randomized clinical trials. J Neurol 265:1871\u20131879","journal-title":"J Neurol"},{"key":"2188_CR42","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.molmed.2007.09.001","volume":"13","author":"CM Mastroianni","year":"2007","unstructured":"Mastroianni CM, Liuzzi GM (2007) Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies. Trends Mol Med 13:449\u2013459","journal-title":"Trends Mol Med"},{"key":"2188_CR43","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ana.22053","volume":"67","author":"JC McArthur","year":"2010","unstructured":"McArthur JC, Steiner J, Sacktor N, Nath A (2010) Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 67:699\u2013714","journal-title":"Ann Neurol"},{"key":"2188_CR44","doi-asserted-by":"crossref","first-page":"815","DOI":"10.7326\/0003-4819-159-12-201312170-00007","volume":"159","author":"CA Meijer","year":"2013","unstructured":"Meijer CA, Stijnen T, Wasser MN, Hamming JF, van Bockel JH, Lindeman JH (2013) Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial. Ann Intern Med 159:815\u2013823","journal-title":"Ann Intern Med"},{"key":"2188_CR45","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1177\/1352458509106779","volume":"15","author":"LM Metz","year":"2009","unstructured":"Metz LM, Li D, Traboulsee A, Myles ML, Duquette P, Godin J, Constantin M, Yong VW (2009) Glatiramer acetate in combination with minocycline in patients with relapsing\u2013remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. Mult Scler 15:1183\u20131194","journal-title":"Mult Scler"},{"key":"2188_CR46","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/ana.20111","volume":"55","author":"LM Metz","year":"2004","unstructured":"Metz LM, Zhang Y, Yeung M, Patry DG, Bell RB, Stoian CA, Yong VW, Patten SB, Duquette P, Antel JP, Mitchell JR (2004) Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 55:756","journal-title":"Ann Neurol"},{"key":"2188_CR47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000468621","volume":"49","author":"P Mignatti","year":"1996","unstructured":"Mignatti P, Rifkin DB (1996) Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 49:117\u2013137","journal-title":"Enzyme Protein"},{"key":"2188_CR48","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.neuron.2010.06.021","volume":"67","author":"JP Miller","year":"2010","unstructured":"Miller JP, Holcomb J, Al-Ramahi I, de Haro M, Gafni J, Zhang N, Kim E, Sanhueza M, Torcassi C, Kwak S, Botas J, Hughes RE, Ellerby LM (2010) Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington\u2019s disease. Neuron 67:199\u2013212","journal-title":"Neuron"},{"key":"2188_CR49","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archneurol.2007.41","volume":"65","author":"A Minagar","year":"2008","unstructured":"Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ (2008) Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. Arch Neurol 65:199\u2013204","journal-title":"Arch Neurol"},{"key":"2188_CR50","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.gene.2018.06.027","volume":"672","author":"S Misra","year":"2018","unstructured":"Misra S, Talwar P, Kumar A, Kumar P, Sagar R, Vibha D, Pandit AK, Gulati A, Kushwaha S, Prasad K (2018) Association between matrix metalloproteinase family gene polymorphisms and risk of ischemic stroke: a systematic review and meta-analysis of 29 studies. Gene 672:180\u2013194","journal-title":"Gene"},{"key":"2188_CR51","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/gps.3846","volume":"28","author":"DW Molloy","year":"2013","unstructured":"Molloy DW, Standish TI, Zhou Q, Guyatt G (2013) A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer\u2019s disease: the DARAD trial. Int J Geriatr Psychiatry 28:463\u2013470","journal-title":"Int J Geriatr Psychiatry"},{"key":"2188_CR52","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.yjmcc.2018.08.026","volume":"123","author":"VA Myasoedova","year":"2018","unstructured":"Myasoedova VA, Chistiakov DA, Grechko AV, Orekhov AN (2018) Matrix metalloproteinases in pro-atherosclerotic arterial remodeling. J Mol Cell Cardiol 123:159\u2013167","journal-title":"J Mol Cell Cardiol"},{"key":"2188_CR53","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1212\/WNL.0b013e31827b9121","volume":"80","author":"N Nakasujja","year":"2013","unstructured":"Nakasujja N, Miyahara S, Evans S, Lee A, Musisi S, Katabira E, Robertson K, Ronald A, Clifford DB, Sacktor N (2013) Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. Neurology 80:196\u2013202","journal-title":"Neurology"},{"key":"2188_CR54","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1749-6632.1986.tb27139.x","volume":"481","author":"C Nicholson","year":"1986","unstructured":"Nicholson C, Rice ME (1986) The migration of substances in the neuronal microenvironmenta. Ann N Y Acad Sci 481:55\u201368","journal-title":"Ann N Y Acad Sci"},{"key":"2188_CR55","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1212\/01.wnl.0000201252.57661.e1","volume":"66","author":"Ninds Net-Pd Investigators","year":"2006","unstructured":"Ninds Net-Pd Investigators (2006) A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66:664\u2013671","journal-title":"Neurology"},{"key":"2188_CR56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/WNF.0b013e3181342f32","volume":"31","author":"Ninds Net-Pd Investigators","year":"2008","unstructured":"Ninds Net-Pd Investigators (2008) A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol 31:141\u2013150","journal-title":"Clin Neuropharmacol"},{"key":"2188_CR57","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4103\/0028-3886.93584","volume":"60","author":"MV Padma Srivastava","year":"2012","unstructured":"Padma Srivastava MV, Bhasin A, Bhatia R, Garg A, Gaikwad S, Prasad K, Singh MB, Tripathi M (2012) Efficacy of minocycline in acute ischemic stroke: a single-blinded, placebo-controlled trial. Neurol India 60:23\u201328","journal-title":"Neurol India"},{"key":"2188_CR58","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0006-2952(96)00168-2","volume":"52","author":"L Paemen","year":"1996","unstructured":"Paemen L, Martens E, Norga K, Masure S, Roets E, Hoogmartens J, Opdenakker G (1996) The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem Pharmacol 52:105\u2013111","journal-title":"Biochem Pharmacol"},{"key":"2188_CR59","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.atherosclerosis.2018.02.012","volume":"271","author":"F Palm","year":"2018","unstructured":"Palm F, Pussinen PJ, Safer A, Tervahartiala T, Sorsa T, Urbanek C, Becher H, Grau AJ (2018) Serum matrix metalloproteinase-8, tissue inhibitor of metalloproteinase and myeloperoxidase in ischemic stroke. Atherosclerosis 271:9\u201314","journal-title":"Atherosclerosis"},{"key":"2188_CR60","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ana.21922","volume":"67","author":"F Pico","year":"2010","unstructured":"Pico F, Jacob MP, Labreuche J, Soufir N, Touboul PJ, Benessiano J, Cambien F, Grandchamp B, Michel JB, Amarenco P (2010) Matrix metalloproteinase-3 and intracranial arterial dolichoectasia. Ann Neurol 67:508\u2013515","journal-title":"Ann Neurol"},{"key":"2188_CR61","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1474-4422(09)70016-X","volume":"8","author":"GA Rosenberg","year":"2009","unstructured":"Rosenberg GA (2009) Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 8:205\u2013216","journal-title":"Lancet Neurol"},{"key":"2188_CR62","doi-asserted-by":"crossref","unstructured":"Rosenberg GA (2017) \u2018Chapter 61 - Matrix Metalloproteinases and Extracellular Matrix in the Central Nervous System.\u2019 in Louis R. Caplan, Jos\u00e9 Biller, Megan C. Leary, Eng H. Lo, Ajith J. Thomas, Midori Yenari and John H. Zhang (eds.), Primer on Cerebrovascular Diseases (Second Edition) (Academic Press: San Diego)","DOI":"10.1016\/B978-0-12-803058-5.00061-8"},{"key":"2188_CR63","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1212\/WNL.46.6.1626","volume":"46","author":"GA Rosenberg","year":"1996","unstructured":"Rosenberg GA, Dencoff JE, Correa N Jr, Reiners M, Ford CC (1996) Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 46:1626\u20131632","journal-title":"Neurology"},{"key":"2188_CR64","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/01.STR.32.5.1162","volume":"32","author":"GA Rosenberg","year":"2001","unstructured":"Rosenberg GA, Sullivan N, Esiri MM (2001) White matter damage is associated with matrix metalloproteinases in vascular dementia. Stroke 32:1162\u20131168","journal-title":"Stroke"},{"key":"2188_CR65","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/0006-291X(90)90780-Q","volume":"171","author":"H Saari","year":"1990","unstructured":"Saari H, Suomalainen K, Lindy O, Konttinen YT, Sorsa T (1990) Activation of latent human neutrophil collagenase by reactive oxygen species and serine proteases. Biochem Biophys Res Commun 171:979\u2013987","journal-title":"Biochem Biophys Res Commun"},{"key":"2188_CR66","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1212\/WNL.0b013e31822f0412","volume":"77","author":"N Sacktor","year":"2011","unstructured":"Sacktor N, Miyahara S, Deng L, Evans S, Schifitto G, Cohen BA, Paul R, Robertson K, Jarocki B, Scarsi K, Coombs RW, Zink MC, Nath A, Smith E, Ellis RJ, Singer E, Weihe J, McCarthy S, Hosey L, Clifford DB (2011) Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology 77:1135\u20131142","journal-title":"Neurology"},{"key":"2188_CR67","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s13365-014-0292-0","volume":"20","author":"N Sacktor","year":"2014","unstructured":"Sacktor N, Miyahara S, Evans S, Schifitto G, Cohen B, Haughey N, Drewes JL, Graham D, Zink MC, Anderson C, Nath A, Pardo CA, McCarthy S, Hosey L, Clifford D (2014) Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment. J Neurovirol 20:620\u2013626","journal-title":"J Neurovirol"},{"key":"2188_CR68","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/sj.jcbfm.9600534","volume":"28","author":"RR Sood","year":"2008","unstructured":"Sood RR, Taheri S, Candelario-Jalil E, Estrada EY, Rosenberg GA (2008) Early beneficial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain. J Cereb Blood Flow Metab 28:431\u2013438","journal-title":"J Cereb Blood Flow Metab"},{"key":"2188_CR69","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/ene.12953","volume":"23","author":"PS S\u00f8rensen","year":"2016","unstructured":"S\u00f8rensen PS, Sellebjerg F, Lycke J, F\u00e4rkkil\u00e4 M, Cr\u00e9ange A, Lund CG, Schluep M, Frederiksen JL, Stenager E, Pfleger C, Garde E, Kinnunen E, Marhardt K (2016) Minocycline added to subcutaneous interferon \u03b2-1a in multiple sclerosis: randomized RECYCLINE study. Eur J Neurol 23:861\u2013870","journal-title":"Eur J Neurol"},{"key":"2188_CR70","first-page":"373","volume":"1762","author":"EC Stack","year":"2006","unstructured":"Stack EC, Smith KM, Ryu H, Cormier K, Chen M, Hagerty SW, Del Signore SJ, Cudkowicz ME, Friedlander RM, Ferrante RJ (2006) Combination therapy using minocycline and coenzyme Q10 in R6\/2 transgenic Huntington\u2019s disease mice. Biochem Biophys Acta 1762:373\u2013380","journal-title":"Biochem Biophys Acta"},{"key":"2188_CR71","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/1073858405275175","volume":"11","author":"DP Stirling","year":"2005","unstructured":"Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W (2005) Minocycline as a neuroprotective agent. Neuroscientist 11:308\u2013322","journal-title":"Neuroscientist"},{"key":"2188_CR72","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/jnnp-2016-313541","volume":"88","author":"D Varges","year":"2017","unstructured":"Varges D, Manthey H, Heinemann U, Ponto C, Schmitz M, Schulz-Schaeffer WJ, Krasnianski A, Breithaupt M, Fincke F, Kramer K, Friede T, Zerr I (2017) Doxycycline in early CJD: a double-blinded randomised phase II and observational study. J Neurol Neurosurg Psychiatry 88:119\u2013125","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2188_CR73","first-page":"908636","volume":"2014","author":"XX Wang","year":"2014","unstructured":"Wang XX, Tan MS, Yu JT, Tan L (2014) Matrix metalloproteinases and their multiple roles in Alzheimer\u2019s disease. Biomed Res Int 2014:908636","journal-title":"Biomed Res Int"},{"key":"2188_CR74","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1177\/1352458506070319","volume":"13","author":"RK Zabad","year":"2007","unstructured":"Zabad RK, Metz LM, Todoruk TR, Zhang Y, Mitchell JR, Yeung M, Patry DG, Bell RB, Yong VW (2007) The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler 13:517\u2013526","journal-title":"Mult Scler"},{"key":"2188_CR75","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1017\/S0317167100008611","volume":"35","author":"Y Zhang","year":"2008","unstructured":"Zhang Y, Metz LM, Yong VW, Bell RB, Yeung M, Patry DG, Mitchell JR (2008) Pilot study of minocycline in relapsing-remitting multiple sclerosis. Can J Neurol Sci 35:185\u2013191","journal-title":"Can J Neurol Sci"},{"key":"2188_CR76","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.293.16.2003","volume":"293","author":"MC Zink","year":"2005","unstructured":"Zink MC, Uhrlaub J, DeWitt J, Voelker T, Bullock B, Mankowski J, Tarwater P, Clements J, Barber S (2005) Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 293:2003\u20132011","journal-title":"JAMA"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-021-02188-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-021-02188-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-021-02188-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T12:12:24Z","timestamp":1699877544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-021-02188-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["2188"],"URL":"https:\/\/doi.org\/10.1007\/s00210-021-02188-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,1]]},"assertion":[{"value":"30 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare consent to publish this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}